CCIA
AKRO

Campbell & Co Investment Adviser’s Akero Therapeutics AKRO Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,649
Closed -$1.5M – 1075
2023
Q3 		$1.5M Buy
29,649
+11,699
+65% +$545K 0.18% 156
2023
Q2 		$838K Buy
+17,950
New +$823K 0.15% 216

Other funds holding AKRO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Campbell & Co Investment Adviser's AKRO Position: Q4 2023 in Review

Campbell & Co Investment Adviser sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 29,649 shares — an estimated $1.5M sold.

Campbell & Co Investment Adviser first reported a position in AKRO in Q2 2023 and held it in 2 quarters. The position peaked at $1.5M in Q3 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

  • Campbell & Co Investment Adviser reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 29,649 Akero Therapeutics shares in Q4 2023, an estimated $1.5M.
  • Campbell & Co Investment Adviser first reported a position in Akero Therapeutics in Q2 2023 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Akero Therapeutics position peaked at $1.5M in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2023, filed 13 Feb 2024.